Clinical Trial Details

MK-3475-775-KEYNOTE-775 USOR 17197

A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer

Purpose/Objective

Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov

Condition: Endometrial Cancer
Study Type: Interventional
Phase: III
Study Start Date: 07/18/2018
Study Completion Date: 01/2023

This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to receive either pembrolizumab and lenvatinib or treatment of physician's choice. The primary study hypothesis is that pembrolizumab in combination with lenvatinib prolongs progression free survival (PFS) and overall survival (OS) when compared to treatment of physician's choice.

 

NCT Number

NCT03517449

Principal Investigator(s)

Cheryl A. Aylesworth, MD

Sponsor(s)

Eisai, Inc

Participant Eligibility

• Age: 18 - No Maximum
• Gender: Male, Female